Abstract
Get full access to this article
View all access options for this article.
References
1.Astellas Pharma. Astellas reports update to September 1 announcement on the ASPIRO clinical trial of at132 in patients with X-linked myotubular myopathy. 2021 . https://www.astellas.com/en/news/17161 (last accessed
September 15 , 2021
).
2.
Philippidis
A
.
Fourth boy dies in trial of
Astellas gene therapy candidate
. Genetic Engineering &
Biotechnology
News
. 2021. https://www.genengnews.com/news/fourth-boy-dies-in-trial-of-astellas-gene-therapy-candidate/ (last accessed
September 15 , 2021
).
3.BioMarin Pharmaceutical. U.S. FDA placed a clinical hold on BMN 307 phearless phase 1/2 gene therapy study in adults with PKU based on interim pre-clinical study findings. 2021 . https://investors.biomarin.com/2021-09-06-U-S-FDA-Placed-a-Clinical-Hold-on-BMN-307-Phearless-Phase-1-2-Gene-Therapy-Study-in-Adults-with-PKU-Based-on-Interim-Pre-clinical-Study-Findings (last accessed
September 15 , 2021
).
4.Shape Therapeutics. Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications. 2021 . https://www.globenewswire.com/news-release/2021/08/24/2285515/0/en/Shape-Therapeutics-enters-into-a-strategic-research-collaboration-with-Roche-to-advance-breakthrough-AAV-based-RNA-editing-technology-for-neuroscience-and-rare-disease-indications.html (last accessed
September 9 , 2021
).
5.
NeuExcell Therapeutics and Spark
Therapeutics
,
a Member of the Roche
Group
.
NeuExcell therapeutics and spark therapeutics announce research collaboration agreement to develop a novel gene therapy for
Huntington's disease
. 2021. https://www.prnewswire.com/news-releases/neuexcell-therapeutics-and-spark-therapeutics-announce-research-collaboration-agreement-to-develop-a-novel-gene-therapy-for-huntingtons-disease-301369445.html (last accessed
September 11 , 2021
).
6.LEXEO Therapeutics. LEXEO therapeutics closes $100 million series B financing. 2021 . https://www.lexeotx.com/post/lexeo-therapeutics-closes-100-million-series-b-financing (last accessed
September 11 , 2021
).
7.iECURE. iECURE launches with $50 million series a financing to develop in vivo gene insertion approaches for devastating diseases. 2021 . https://www.businesswire.com/news/home/20210909005273/en/iECURE-Launches-With-50-Million-Series-A-Financing-to-Develop-In-Vivo-Gene-Insertion-Approaches-for-Devastating-Diseases (last accessed
September 11 , 2021
).